- Home
- GCTK vs PRFX Comparison
GCTK vs PRFX Comparison
Compare GCTK & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- PRFX
- Stock Information
- Founded
- GCTK 2001
- PRFX 2007
- Country
- GCTK United States
- PRFX Israel
- Employees
- GCTK N/A
- PRFX N/A
- Industry
- GCTK Medical/Dental Instruments
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- PRFX Health Care
- Exchange
- GCTK Nasdaq
- PRFX Nasdaq
- Market Cap
- GCTK 3.3M
- PRFX 2.8M
- IPO Year
- GCTK N/A
- PRFX 2020
- Fundamental
- Price
- GCTK $5.72
- PRFX $1.34
- Analyst Decision
- GCTK
- PRFX Hold
- Analyst Count
- GCTK 0
- PRFX 1
- Target Price
- GCTK N/A
- PRFX N/A
- AVG Volume (30 Days)
- GCTK 81.7K
- PRFX 87.4K
- Earning Date
- GCTK 08-14-2025
- PRFX 08-29-2025
- Dividend Yield
- GCTK N/A
- PRFX N/A
- EPS Growth
- GCTK N/A
- PRFX N/A
- EPS
- GCTK N/A
- PRFX N/A
- Revenue
- GCTK N/A
- PRFX N/A
- Revenue This Year
- GCTK N/A
- PRFX N/A
- Revenue Next Year
- GCTK N/A
- PRFX N/A
- P/E Ratio
- GCTK N/A
- PRFX N/A
- Revenue Growth
- GCTK N/A
- PRFX N/A
- 52 Week Low
- GCTK $5.11
- PRFX $1.25
- 52 Week High
- GCTK $3,756.00
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- GCTK 42.45
- PRFX 41.21
- Support Level
- GCTK $5.64
- PRFX $1.32
- Resistance Level
- GCTK $5.98
- PRFX $1.55
- Average True Range (ATR)
- GCTK 0.37
- PRFX 0.07
- MACD
- GCTK -0.03
- PRFX 0.01
- Stochastic Oscillator
- GCTK 11.65
- PRFX 37.50
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.